This maintained tracker follows peptides in PeptaHub's legal_status dataset that are currently marked reclassification-pending. It is built for readers who need a quick, citeable view of which compounds are still waiting on formal FDA movement, which ones have stronger caution flags, and what the current PeptaHub note says for each peptide.
The tracker is educational only. It does not provide dosing, sourcing, compounding instructions, or medical advice. Legal status can change quickly, and FDA publications, state board rules, pharmacy policies, and prescriber judgment all matter.
Reclassification table
Last updated: June 9, 2026. This YMYL tracker is generated from published PeptaHub peptide entries marked reclassification-pending.
| AOD-9604 | Reclassification pending | Awaiting formal FDA or compounding-policy update | Under FDA reclassification review. Approved in Australia as a complementary medicine ingredient. Available from compounding pharmacies in several countries. |
| BPC-157 | Reclassification pending | Awaiting formal FDA or compounding-policy update | One of 14 peptides under FDA reclassification review (RFK Jr. initiative). Previously available from research chemical suppliers; most US vendors ceased sales in 2025-2026. |
| CJC-1295 | Reclassification pending | Awaiting formal FDA or compounding-policy update | Under FDA reclassification review as part of the 14-peptide RFK Jr. initiative. Previously available from research peptide suppliers. |
| GHRP-2 | Reclassification pending | Awaiting formal FDA or compounding-policy update | GHRP-2 was placed on the FDA Category 2 bulk drug substance list in September 2023, banning compounding pharmacy preparation in the US. Industry analysis as of February 2026 suggests GHRP-2 is among the peptides expected to remain on Category 2 (due to cortisol and prolactin elevation concerns) rather than returning to compounding-eligible status. No formal FDA update published as of April 2026. Approved as a diagnostic agent in Japan. |
| GHRP-6 | Reclassification pending | Awaiting formal FDA or compounding-policy update | GHRP-6 was placed on the FDA Category 2 bulk drug substance list in September 2023, banning compounding pharmacy preparation in the US. Industry analysis as of February 2026 indicates GHRP-6 is among the ~5 peptides expected to remain on Category 2 (alongside GHRP-2, Melanotan II, LL-37, and PEG-MGF) due to cortisol/prolactin elevation and appetite stimulation concerns. No formal FDA update published as of April 2026. |
| Ipamorelin | Reclassification pending | Awaiting formal FDA or compounding-policy update | Under FDA reclassification review. Previously available as a research peptide. |
| Mod GRF 1-29 | Reclassification pending | Awaiting formal FDA or compounding-policy update | One of 14 peptides under FDA reclassification review (RFK Jr. initiative, 2025–2026). Previously available from US compounding pharmacies as a GHRH analog; most commercial availability ceased 2024–2025. Research-use supply chains remain active internationally. |
| Sermorelin | Reclassification pending | Awaiting formal FDA or compounding-policy update | Previously FDA-approved (Geref, 1997). Discontinued commercially in 2008 but still available through compounding pharmacies. Under reclassification review. |
| TB-500 | Reclassification pending | Awaiting formal FDA or compounding-policy update | Under FDA reclassification review. Previously classified as a research chemical. Widely used in veterinary medicine. |
| Thymosin Beta-4 | Reclassification pending | Awaiting formal FDA or compounding-policy update | Thymosin Beta-4 (full protein) is subject to the same FDA compounding ban framework that covers TB-500, as a peptide exceeding 40 amino acids. One of 14 peptides under FDA reclassification review (RFK Jr. initiative, 2025–2026). Availability from US compounding pharmacies is restricted; research supply chains remain active. |
How to read this tracker
The table below pulls directly from PeptaHub peptide profile data where legal_status equals reclassification-pending. The current status column translates that dataset flag into reader-facing language. The reclassification status column summarizes the review posture without implying that FDA has approved, cleared, or authorized a peptide unless the source data says so.
The note column is the current legal_notes field from the peptide dataset. It is intentionally concise: this page is a maintained tracker, not a replacement for FDA source documents, pharmacy counsel, or the full peptide profile pages.
Tracker maintenance policy
PeptaHub updates this page when the underlying peptide dataset changes, when FDA publishes relevant bulk-substance or compounding guidance, or when a peptide's market status materially changes. Each update should preserve the table shape so journalists, community moderators, and researchers can compare the same compounds over time.
If a peptide leaves reclassification-pending status in the dataset, it should drop out of this table on the next page update and be handled in the appropriate profile, comparison, or regulatory timeline entry.
Editorial caution
Reclassification-pending is not the same thing as FDA approval, prescription access, or legal availability. It means PeptaHub has tagged the compound as awaiting a clearer FDA or compounding-policy outcome. Readers should not treat inclusion in this table as a signal to buy, compound, prescribe, or use a peptide.
This topic is YMYL because it touches regulated health products. PeptaHub frames the page as a status tracker and citation aid only.
Cite this tracker
PeptaHub Editorial Team. FDA Peptide Reclassification Tracker 2026. PeptaHub. Updated June 9, 2026. https://peptahub.com/guides/fda-reclassification-2026
Frequently asked questions
No. Reclassification-pending means PeptaHub's dataset marks the peptide as awaiting a clearer FDA or compounding-policy outcome. It does not mean the peptide is FDA-approved, available by prescription, or legally available from a compounding pharmacy.
The table is generated from PeptaHub's peptide dataset by filtering for entries where legal_status is reclassification-pending. The status notes come from each peptide's legal_notes field.
It should be updated whenever the source peptide dataset changes, when FDA publishes relevant compounding or bulk-substance guidance, or when a peptide's practical market status changes materially.
No. This page is educational only and does not provide dosing, sourcing, compounding, prescribing, or treatment instructions.